NCT05970744View on ClinicalTrials.gov

Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

June 19, 2023

Study Completion Date

September 18, 2023

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV/Flu-01E low dose

Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus

BIOLOGICAL

RSV/Flu-01E high dose

Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus

BIOLOGICAL

Placebo

Participants will receive single intranasal injection of Placebo

Trial Locations (1)

Unknown

Smorodintsev Research Institute of Influenza, Saint Petersburg

All Listed Sponsors
lead

Tatyana Zubkova

OTHER

NCT05970744 - Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years | Biotech Hunter | Biotech Hunter